Since it can be speculated that the depression experienced in these diseases results from enhanced ELK-1 activity, inhibiting ELK-1 with TDE peptide might alleviate depressive symptoms in people with these diseases. This evidence concerns the gene ELK1 and depressive symptom measurement.